Abstract
Idiopathic pulmonary fibrosis (IPF), or usual interstitial pneumonitis (UIP) is one of the most common causes of pulmonary fibrosis. It is characterized by progressive fibrosis of both lungs. The diagnosis is usually made on the basis of high resolution CT scan of chest or open lung biopsy. Treatment for UIP has been mainly empirical. Besides lung transplant, no clear-cut medical therapy has emerged. In 2010 European union approved pirfenidone. The approval by this drug lagged in USA. On October 15th 2014, Food and Drug Administration (FDA) approved Nintedanib and Pirfenidone for patient use in United States of America. We present a brief commentary on the basic disease process and the new emerging therapies.
Keywords: IPF, nintedanib, pirfenidone, UIP.
Current Respiratory Medicine Reviews
Title:Emerging Approved Treatments for Idiopathic Pulmonary Fibrosis: Some Hope for Patients?
Volume: 10 Issue: 4
Author(s): Shawn Johnson and Salim Surani
Affiliation:
Keywords: IPF, nintedanib, pirfenidone, UIP.
Abstract: Idiopathic pulmonary fibrosis (IPF), or usual interstitial pneumonitis (UIP) is one of the most common causes of pulmonary fibrosis. It is characterized by progressive fibrosis of both lungs. The diagnosis is usually made on the basis of high resolution CT scan of chest or open lung biopsy. Treatment for UIP has been mainly empirical. Besides lung transplant, no clear-cut medical therapy has emerged. In 2010 European union approved pirfenidone. The approval by this drug lagged in USA. On October 15th 2014, Food and Drug Administration (FDA) approved Nintedanib and Pirfenidone for patient use in United States of America. We present a brief commentary on the basic disease process and the new emerging therapies.
Export Options
About this article
Cite this article as:
Johnson Shawn and Surani Salim, Emerging Approved Treatments for Idiopathic Pulmonary Fibrosis: Some Hope for Patients?, Current Respiratory Medicine Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/1573398X11666141208233106
DOI https://dx.doi.org/10.2174/1573398X11666141208233106 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development and Significance of the Frailty Concept in the Elderly: A Possible Modern View
CNS & Neurological Disorders - Drug Targets Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Blood-Based Biomarkers of Alzheimer´s Disease: Diagnostic Algorithms and New Technologies
Current Alzheimer Research Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Current Pharmaceutical Design Gender Differences in Cancer-associated Venous Thromboembolism
Current Medicinal Chemistry The Parathyroid Hormone Receptorsome and the Potential for Therapeutic Intervention
Current Drug Targets Mechanisms of Brain Signaling During Sepsis
Current Neuropharmacology Ex Vivo and In Vivo Approaches to Study Mechanisms of Cardioprotection Targeting Ischemia/Reperfusion (I/R) Injury: Useful Techniques for Cardiovascular Drug Discovery
Current Drug Discovery Technologies Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns
Current Genomics Isomannide and Derivatives. Chemical and Pharmaceutical Applications
Mini-Reviews in Organic Chemistry Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design PC9, A New Actor in Autosomal Dominant Hypercholesterolemia
Current Genomics Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Association Between Vitamin D Serum Level and Depression
Current Psychopharmacology Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Electroporation: An Effective Method For <i>In Vivo</i> Gene Delivery
Drug Delivery Letters Retinoids: Impact on Adiposity, Lipids and Lipoprotein Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery